Cancer treatment for sufferers of aggressive cancers may be revolutionised by new research from Singapore's Agency for Scientific Technology and Research (A*STAR).
Developers hope the findings will pioneer effective and affordable mainstream cancer vaccination for patients.
The new technique allows antibodies to target intracellular components like the PRL-3 oncoprotein. Previously, it was believed that the antibodies could only bind to extracellular cancer proteins.
Dr Zeng, of A*STAR, commented: "This means that a whole new list of intracellular oncoproteins previously thought to be untargetable … can now be potentially targeted".
He believes this will boost the possibilities for tailor-made antibody therapy as well as launch a new era of tailor-made cancer vaccines.
When the PRL-3 antibodies were tested on mice, results revealed a 70 to 90 per cent decrease in tumours derived from PRL-3 oncoproteins.
NHS figures show there are approximately 298,000 new incidences of cancer diagnosed each year in the UK and more than one in three people will suffer cancer at some stage of their life.